Q3 2025 Indoco Remedies Ltd Earnings Call Transcript
Key Points
- Indoco Remedies Ltd (BOM:532612) has a strong order book for international formulations business to Europe and US, standing at about INR180 crores.
- The company's largest brand, Cyclopam, has shown significant growth, reaching INR175 crores with a growth rate exceeding 20%.
- New product introductions now form 4.8% of the top line, surpassing the industry benchmark of 2.8%.
- Indoco Remedies Ltd received final ANDA approval from the US FDA for Cetirizine Hydrochloride tablets and Varenicline tablets, expanding their product offerings.
- The company entered into a strategic distribution partnership with Clarity Pharma UK, which is expected to enhance their market reach.
- The supply side for international formulations business has been severely impacted, particularly due to a warning letter from the FDA regarding the sterile plant in Goa.
- Sales to regulated markets of the US and EU have decreased by INR90 crores YoY for the quarter, significantly affecting revenues.
- The EBITDA to net sales ratio has dropped to 5.5% from 14.6% in the same quarter last year, indicating reduced profitability.
- The company is incurring additional fixed costs due to the acquisition of a front end in the US, impacting the P&L without corresponding revenue output.
- Remediation costs related to compliance issues are expected to continue for at least two more quarters, affecting financial performance.
Ladies and gentlemen, good day, and welcome to Indoco Remedies Q3 FY25 earnings conference call hosted by Dolat Capital Markets Private Limited. (Operator Instructions)
I now hand the conference over to Ms. Rashmi Shetty from Dolat Capital. Thank you, and over to you.
Thank you, Steve. Good afternoon, everyone. I, Rashmi Shetty, on behalf of Dolat Capital, welcome you all on the Q3 FY25 earnings concall of Indoco Remedies.
I would like to thank the management of Indoco Remedies for giving us this opportunity to host the call. Today from the management team, we have with us Ms. Aditi Panandikar, Managing Director; Mr. Sundeep Bambolkar, Joint Managing Director; and Mr. Pramod Ghorpade, CFO.
I now hand over the call to the management for the opening remarks. Over to you, sir.
Rashmi, thank you very much. Good afternoon, everyone. Thank you for joining this call today.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
